218 related articles for article (PubMed ID: 19524946)
41. What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
Diekstra MH; Liu X; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jan; 18(1):1-4. PubMed ID: 27967336
[No Abstract] [Full Text] [Related]
42. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-2 based therapy for kidney cancer.
Dutcher JP
Cancer Treat Res; 2003; 116():155-72. PubMed ID: 14650831
[TBL] [Abstract][Full Text] [Related]
44. Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2.
Gunawardane ND; Vaghani SP; Kuzel TM; Cotliar JA
J Am Acad Dermatol; 2013 Oct; 69(4):e183-4. PubMed ID: 24034391
[No Abstract] [Full Text] [Related]
45. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
46. Renal cell carcinoma: a model system for novel drug development?
Bukowski RM
Clin Genitourin Cancer; 2008 Mar; 6(1):7-8. PubMed ID: 18501076
[No Abstract] [Full Text] [Related]
47. Times to event: why are they hard to visualize?
Wittes J
J Natl Cancer Inst; 2008 Jan; 100(2):80-1. PubMed ID: 18182615
[No Abstract] [Full Text] [Related]
48. High-dose interleukin-2 is an intensive treatment regardless of the venue of administration.
Schwartzentruber DJ
Cancer J; 2001; 7(2):103-4. PubMed ID: 11324761
[No Abstract] [Full Text] [Related]
49. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer.
Yagoda A; Bander NH
Urol Int; 1989; 44(6):338-45. PubMed ID: 2696193
[TBL] [Abstract][Full Text] [Related]
50. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
51. Managing the complex journey of renal cell carcinoma.
Amen K
ONS Connect; 2007; 22(8 Suppl):53-4. PubMed ID: 17824565
[No Abstract] [Full Text] [Related]
52. Third-Line Treatment Options for Kidney Cancer.
Posadas EM; Limvorasak S; Figlin RA
Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
[No Abstract] [Full Text] [Related]
53. Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
Tourani JM; Grise P; Lucas V; Mayeur D; Dufour B; Di Palma M; Boaziz C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Untereiner M
Cancer Biother Radiopharm; 1996 Oct; 11(5):297-300. PubMed ID: 10851507
[No Abstract] [Full Text] [Related]
54. An unusual case of renal carcinoma.
Zell JA; Iyer PR; Kukes GD; Beamon DB
Pathology; 2006 Aug; 38(4):370-1. PubMed ID: 16916734
[No Abstract] [Full Text] [Related]
55. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
56. [Advice from Public Health Council concerning administration of interleukin-2 in patients with renal cell tumor].
van Maanen L
Oncologica; 1994 May; 11(2):31-2. PubMed ID: 8025832
[No Abstract] [Full Text] [Related]
57. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
58. Interleukin-2 therapy for renal cell cancer: indications, effects, and nursing implications.
Letizia M; Conway AM
Crit Care Nurse; 1996 Oct; 16(5):20-6, 30-2, 34-5. PubMed ID: 9004585
[No Abstract] [Full Text] [Related]
59. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
Pal SK; Bergerot P; Dizman N; Bergerot C; Adashek J; Madison R; Chung JH; Ali SM; Jones JO; Salgia R
Eur Urol; 2018 Jul; 74(1):124-128. PubMed ID: 29685646
[No Abstract] [Full Text] [Related]
60. The dark side of targeted therapy.
Karam JA; Wood CG
Eur Urol; 2011 Apr; 59(4):541-2. PubMed ID: 21295398
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
